On Tuesday, Neurocrine Biosciences, Inc (NASDAQ: NBIX) was 0.35% up from the session before settling in for the closing price of $124.56. A 52-week range for NBIX has been $84.23 – $157.98.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 24.48% over the past five years. When this article was written, the company’s average yearly earnings per share was at 21.64%. With a float of $95.47 million, this company’s outstanding shares have now reached $99.00 million.
Let’s look at the performance matrix of the company that is accounted for 1800 employees. In terms of profitability, gross margin is 98.25%, operating margin of 20.61%, and the pretax margin is 19.32%.
Neurocrine Biosciences, Inc (NBIX) Insider Updates
Also, it is sometimes useful to examine the sentiment of large-scale investors toward Neurocrine Biosciences, Inc stocks. The insider ownership of Neurocrine Biosciences, Inc is 3.53%, while institutional ownership is 94.24%. The most recent insider transaction that took place on May 27 ’25, was worth 1,157,211. In this transaction Director of this company sold 9,613 shares at a rate of $120.38, taking the stock ownership to the 514,596 shares. Before that another transaction happened on May 27 ’25, when Company’s Director proposed sale 9,613 for $120.18, making the entire transaction worth $1,155,290.
Neurocrine Biosciences, Inc (NBIX) Performance Highlights and Predictions
According to the Wall Street analysts, stocks earnings will be around 21.64% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 34.79% during the next five years compared to 53.47% growth over the previous five years of trading.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Trading Performance Indicators
You can see what Neurocrine Biosciences, Inc (NBIX) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 5.13. Likewise, its price to free cash flow for the trailing twelve months is 25.13.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 2.95, a number that is poised to hit 0.98 in the next quarter and is forecasted to reach 5.96 in one year’s time.
Technical Analysis of Neurocrine Biosciences, Inc (NBIX)
Neurocrine Biosciences, Inc (NASDAQ: NBIX) saw its 5-day average volume 1.26 million, a negative change from its year-to-date volume of 1.46 million. As of the previous 9 days, the stock’s Stochastic %D was 79.67%. Additionally, its Average True Range was 3.61.
During the past 100 days, Neurocrine Biosciences, Inc’s (NBIX) raw stochastic average was set at 57.93%, which indicates a significant decrease from 87.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 16.72% in the past 14 days, which was lower than the 49.73% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $110.64, while its 200-day Moving Average is $122.44. Nevertheless, the first resistance level for the watch stands at $126.42 in the near term. At $127.83, the stock is likely to face the second major resistance level. The third major resistance level sits at $129.34. If the price goes on to break the first support level at $123.50, it is likely to go to the next support level at $121.99. Assuming the price breaks the second support level, the third support level stands at $120.58.
Neurocrine Biosciences, Inc (NASDAQ: NBIX) Key Stats
There are 98,966K outstanding shares of the company, which has a market capitalization of 12.37 billion. As of now, sales total 2,355 M while income totals 341,300 K. Its latest quarter income was 572,600 K while its last quarter net income were 7,900 K.
